slide-01 slide-02 Screen4

Technology Platform

image-01

VaxInnate's Technology Platform is revolutionizing how vaccines are created and produced.

Explore

Product Pipeline

image-02

Learn more about our vaccines currently in our development pipeline

View

In The News

VAX2012Q-90

19 Mar 2014 - VaxInnate Begins Phase I Clinical Trial to Evaluate Quadrivalent Vaccine for Prevention of Seasonal Flu

CRANBURY, NJ, March 19, 2014 – VaxInnate Corporation today announced that enrollment has commenced in a Phase 1 clinical trial to evaluate VAX2012Q, a recombinant quadrivalent vaccine in development for the prevention of seasonal influenza. VaxInnate is a biotechnology firm pioneering a breakthrough technology platform for the development of novel vaccines. The VAX2012Q clinical trial […]

Read